Subjects -> MEDICAL SCIENCES (Total: 8359 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (210 journals)
    - ANAESTHESIOLOGY (119 journals)
    - CARDIOVASCULAR DISEASES (329 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (228 journals)
    - DENTISTRY (288 journals)
    - DERMATOLOGY AND VENEREOLOGY (162 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (119 journals)
    - ENDOCRINOLOGY (148 journals)
    - FORENSIC SCIENCES (41 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (182 journals)
    - GERONTOLOGY AND GERIATRICS (132 journals)
    - HEMATOLOGY (153 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (164 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (98 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2268 journals)
    - NURSES AND NURSING (356 journals)
    - OBSTETRICS AND GYNECOLOGY (202 journals)
    - ONCOLOGY (377 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (136 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (164 journals)
    - OTORHINOLARYNGOLOGY (80 journals)
    - PATHOLOGY (96 journals)
    - PEDIATRICS (270 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (152 journals)
    - PSYCHIATRY AND NEUROLOGY (813 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (190 journals)
    - RESPIRATORY DISEASES (102 journals)
    - RHEUMATOLOGY (76 journals)
    - SPORTS MEDICINE (78 journals)
    - SURGERY (393 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (150 journals)

RESPIRATORY DISEASES (102 journals)                     

Showing 1 - 102 of 102 Journals sorted alphabetically
Advances in Respiratory Medicine     Open Access   (Followers: 7)
American Journal of Respiratory and Critical Care Medicine     Full-text available via subscription   (Followers: 255)
American Journal of Respiratory Cell and Molecular Biology     Full-text available via subscription   (Followers: 20)
American Review of Respiratory Disease     Full-text available via subscription   (Followers: 4)
Angiologia e Cirurgia Vascular     Open Access   (Followers: 1)
Annals of the American Thoracic Society     Full-text available via subscription   (Followers: 16)
Annals of Thoracic Medicine     Open Access   (Followers: 6)
Archivos de Bronconeumología     Full-text available via subscription  
Archivos de Bronconeumología (English Edition)     Full-text available via subscription   (Followers: 1)
Asthma Research and Practice     Open Access   (Followers: 1)
BMC Pulmonary Medicine     Open Access   (Followers: 4)
BMJ Open Respiratory Research     Open Access   (Followers: 5)
Breathe     Open Access   (Followers: 4)
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine     Hybrid Journal  
Canadian Respiratory Journal     Open Access   (Followers: 2)
Case Reports in Pulmonology     Open Access   (Followers: 3)
Chest     Full-text available via subscription   (Followers: 100)
Chest Disease Reports     Open Access   (Followers: 2)
Chronic Respiratory Disease     Hybrid Journal   (Followers: 9)
Clinical Lung Cancer     Hybrid Journal   (Followers: 5)
Clinical Medicine Insights : Circulatory, Respiratory and Pulmonary Medicine     Open Access   (Followers: 3)
Clinical Pulmonary Medicine     Hybrid Journal   (Followers: 2)
COPD Research and Practice     Open Access   (Followers: 1)
COPD: Journal of Chronic Obstructive Pulmonary Disease     Hybrid Journal   (Followers: 15)
Current Opinion in Pulmonary Medicine     Hybrid Journal   (Followers: 10)
Current Pulmonology Reports     Hybrid Journal  
Current Research in Tuberculosis     Open Access   (Followers: 3)
Current Respiratory Care Reports     Hybrid Journal   (Followers: 1)
Current Respiratory Medicine Reviews     Hybrid Journal   (Followers: 5)
Der Pneumologe     Hybrid Journal   (Followers: 1)
Egyptian Journal of Chest Diseases and Tuberculosis     Open Access   (Followers: 3)
ERJ Open Research     Open Access   (Followers: 2)
Eurasian Journal of Pulmonology     Open Access  
European Clinical Respiratory Journal     Open Access   (Followers: 3)
European Respiratory Journal     Full-text available via subscription   (Followers: 38)
European Respiratory Review     Open Access   (Followers: 7)
Experimental Lung Research     Hybrid Journal  
Expert Review of Respiratory Medicine     Hybrid Journal   (Followers: 5)
Heart & Lung: The Journal of Acute and Critical Care     Hybrid Journal   (Followers: 11)
Heart, Lung and Circulation     Full-text available via subscription   (Followers: 9)
Indian Journal of Respiratory Care     Open Access   (Followers: 3)
Indian Journal of Tuberculosis     Full-text available via subscription  
Influenza and Other Respiratory Viruses     Open Access   (Followers: 3)
International Journal of Chronic Obstructive Pulmonary Disease     Open Access   (Followers: 3)
Journal of Association of Chest Physicians     Open Access   (Followers: 2)
Journal of Asthma     Hybrid Journal   (Followers: 4)
Journal of Asthma Allergy Educators     Hybrid Journal   (Followers: 4)
Journal of Bronchology & Interventional Pulmonology     Hybrid Journal   (Followers: 3)
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases     Open Access  
Journal of Heart and Lung Transplantation     Hybrid Journal   (Followers: 12)
Journal of Respiratory Medicine     Open Access   (Followers: 4)
Journal of Respiratory Research     Open Access   (Followers: 1)
Journal of Tuberculosis Research     Open Access   (Followers: 1)
Jurnal Respirasi     Open Access  
Karger Kompass Pneumologie     Full-text available via subscription   (Followers: 1)
Kindheit und Entwicklung     Hybrid Journal  
Lung     Hybrid Journal   (Followers: 2)
Lung Cancer     Hybrid Journal   (Followers: 15)
Lung Cancer International     Open Access   (Followers: 2)
Lung Cancer: Targets and Therapy     Open Access   (Followers: 3)
Lung India     Open Access   (Followers: 1)
Multidisciplinary Respiratory Medicine     Open Access   (Followers: 4)
npj Primary Care Respiratory Medicine     Open Access   (Followers: 2)
Open Journal of Respiratory Diseases     Open Access   (Followers: 1)
Open Respiratory Medicine Journal     Open Access   (Followers: 1)
Paediatric Respiratory Reviews     Hybrid Journal   (Followers: 11)
Pediatric Quality & Safety     Open Access  
Pediatric Respirology and Critical Care Medicine     Open Access   (Followers: 1)
Pulmonary Circulation     Open Access   (Followers: 4)
Pulmonary Medicine     Open Access   (Followers: 2)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pulmonary Therapy     Open Access   (Followers: 1)
Pulmonology and Respiratory Research     Open Access   (Followers: 1)
Respiratory Care     Full-text available via subscription   (Followers: 10)
Respiratory Investigation     Full-text available via subscription  
Respiratory Medicine     Hybrid Journal   (Followers: 17)
Respiratory Medicine : X     Open Access  
Respiratory Medicine Case Reports     Open Access  
Respiratory Medicine CME     Hybrid Journal  
Respiratory Medicine Extra     Full-text available via subscription   (Followers: 1)
Respiratory Physiology & Neurobiology     Hybrid Journal   (Followers: 4)
Respiratory Research     Open Access   (Followers: 1)
Respirology     Hybrid Journal   (Followers: 5)
Respirology Case Reports     Open Access  
Revista Americana de Medicina Respiratoria     Open Access  
Revista Chilena de Enfermedades Respiratorias     Open Access  
Revista Inspirar     Open Access  
Revista ORL     Open Access  
Revista Portuguesa de Pneumologia     Open Access  
Sarcoidosis Vasculitis and Diffuse Lung Disese     Full-text available via subscription   (Followers: 3)
Seminars in Respiratory and Critical Care Medicine     Hybrid Journal   (Followers: 14)
Sleep Medicine Reviews     Hybrid Journal   (Followers: 17)
The Clinical Respiratory Journal     Hybrid Journal   (Followers: 3)
The International Journal of Tuberculosis and Lung Disease     Full-text available via subscription   (Followers: 8)
The Lancet Respiratory Medicine     Full-text available via subscription   (Followers: 32)
Therapeutic Advances in Chronic Disease     Open Access   (Followers: 7)
Therapeutic Advances in Respiratory Disease     Open Access   (Followers: 1)
Thorax     Hybrid Journal   (Followers: 37)
Translational Respiratory Medicine     Open Access   (Followers: 1)
Tuberculosis     Hybrid Journal   (Followers: 12)
Tuberculosis Research and Treatment     Open Access   (Followers: 3)
Пульмонология     Full-text available via subscription  

           

Similar Journals
Journal Cover
Respiratory Medicine
Journal Prestige (SJR): 1.472
Citation Impact (citeScore): 3
Number of Followers: 17  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 0954-6111
Published by Elsevier Homepage  [3161 journals]
  • Evaluating the FEV1/FVC ratio in the lower range of normality as a marker
           of worse clinical outcomes in asthmatic subjects without airway
           obstruction
    • Abstract: Publication date: Available online 20 January 2020Source: Respiratory MedicineAuthor(s): Cintia Mingotti, Jose Sarinho, Katia Stanigher, Juçara Silva, Eduardo Roquette, Evaldo Marchi, Eduardo Vieira PonteAbstractBackgroundWe should continually improve tools for evaluating asthma. The aim of this study was to evaluate whether the FEV1/FVC ratio in the lower range of normality is associated with worse outcomes in asthmatics without airway obstruction.MethodsWe screened asthmatics at eight clinics. Subjects answered the Asthma Control Questionnaire and underwent spirometry. We assigned individuals without airway obstruction in three groups according to the post bronchodilator FEV1/FVC ratio: lower range of normality, intermediary range of normality and upper range of normality. Asthma outcomes were hospital admission due to asthma during the preceding year, non-controlled asthma symptoms and moderate-high inhaled maintenance therapy need.ResultsIn subjects from six to 18 years old, the rate of hospital admission was higher in the group with FEV1/FVC ratio in the lower range of normality as compared with the other two groups but the frequency of non-controlled symptoms of asthma and moderate-high dose of inhaled maintenance therapy need was similar. From 19 to 59 years old, the rate of moderate-high inhaled maintenance therapy need was higher in the group with FEV1/FVC ratio in the lower range of normality as compared with the other two groups, but the frequency of hospital admissions and non-controlled symptoms of asthma was similar. Above 59 years old, there was no difference in clinical asthma outcomes between lung function groups.ConclusionsFEV1/FVC ratio in the lower range of normality is a marker of worse clinical outcomes in asthmatics without airway obstruction.
       
  • Long-term effects of web-based pedometer-mediated intervention on COPD
           exacerbations
    • Abstract: Publication date: Available online 11 January 2020Source: Respiratory MedicineAuthor(s): Emily S. Wan, Ana Kantorowski, Madeline Polak, Reema Kadri, Caroline R. Richardson, David R. Gagnon, Eric Garshick, Marilyn L. MoyAbstractBackgroundTechnology-based physical activity (PA) interventions have been shown to improve daily step counts and health-related quality of life, but their effect on long-term clinical outcomes like acute exacerbations (AEs) is unknown in persons with COPD.MethodsU.S. Veterans with stable COPD were randomized (1:1) to either pedometer alone (control) or pedometer plus a website with feedback, goal-setting, disease education, and a community forum (intervention) for 3 months. AEs were assessed every 3 months over a follow-up period of approximately 15 months. Pedometer-assessed daily step counts, health-related quality-of-life (HRQL), and self-efficacy were assessed at baseline, end-of-intervention at 3 months, and during follow-up approximately 6 and 12 months after enrollment. Zero-inflated Poisson models assessed the effect of the intervention on risk for AEs, compared to controls. Generalized linear mixed-effects models for repeated measures examined between-group and within-group changes in daily step count, HRQL, and self-efficacy.ResultsThere were no significant differences in age, FEV1% predicted, baseline daily step count, AEs the year prior to enrollment, or duration of follow-up between the intervention (n = 57) and control (n = 52) groups. The intervention group had a significantly reduced risk of AEs (rate ratio = 0.51, [95%CI 0.31–0.85]), compared to the control group. There were no significant between-group differences in change in average daily step count, HRQL, or self-efficacy at 6 and 12 months after enrollment.ConclusionsA 3-month internet-mediated, pedometer-based PA intervention was associated with reduced risk for AEs in COPD over 12–15 months of follow-up.ClinicalTrials.gov identifier: NCT01772082.
       
  • Comparison of the effects of pulmonary and extra-pulmonary symptoms on
           health-related quality of life in patients with severe asthma
    • Abstract: Publication date: Available online 10 January 2020Source: Respiratory MedicineAuthor(s): Joseph W. Lanario, Michael E. Hyland, Yinghui Wei, Rupert C. Jones, Matthew MasoliAbstractObjectivesTo survey the frequency of extra-pulmonary symptoms reported by a sample of patients with severe asthma, their contribution to quality of life and relationship to treatment pathways.MethodsConsenting patients (N = 100) attending a severe asthma clinic completed questionnaire measures of extra-pulmonary symptoms (the General symptom Questionnaire, GSQ), pulmonary symptoms (Asthma Control Test, ACT), quality of life (the Severe Asthma Questionnaire, SAQ) and health status (EQ-5D-5L).ResultsA median of 21 extra-pulmonary symptoms were reported per week. GSQ correlated −0.65 with the ACT and 0.69 with the SAQ. Linear regression showed that both the ACT and GSQ were significant predictors of SAQ mean score, p 
       
  • Elevated eosinophils, IL5 and IL8 in induced sputum in asthma patients
           with accelerated FEV1 decline
    • Abstract: Publication date: Available online 10 January 2020Source: Respiratory MedicineAuthor(s): Mateja Marc-Malovrh, Luka Camlek, Sabina Škrgat, Izidor Kern, Matjaž Fležar, Manca Dežman, Peter KorošecAbstractBackgroundSome patients with asthma present with accelerated lung function decline. This phenomenon is mostly associated with severe exacerbations and with poor asthma control.ObjectiveOur aim was to detect the extent of FEV1 decline in patients with mild asthma and to discriminate clinical, functional and inflammatory factors associated with accelerated FEV1 decline.MethodsWe recruited 50 patients with mild asthma for pulmonary function testing and induced sputum sampling 12–15 years after the initial diagnosis. In 33 patients, from whom sputum of a good quality was obtained, inflammatory cells were counted and concentrations of cytokines IL-2, IL-4, IL-5, IL-8, IL-10, IFN-γ, angiogenin and VEGF in the sputum were measured by cytometric bead array.ResultsEighteen of 33 patients presented with accelerated FEV1 decline of more than 30 ml/year, with a mean (SEM) of 43.2 (3.9) ml/year, compared to 15 control patients with a FEV1 decline of 14.4 (2.1) ml/year. In the accelerated FEV1 decline group, we found elevated sputum levels of IL5 with a median (IQR) of 1.8 (0.4–3.2) pg/ml vs. 0.2 (0.1–1.2) pg/ml, p = 0.04; IL8 with a mean (SEM) of 1503 (194) pg/ml vs. 938 (177) pg/ml, p = 0.04; and eosinophils with a median (IQR) of 223 (41–1020) cells/μl vs. 39 (1–190) cells/μl, p = 0.03. No significant differences in other measured parameters were detected between the two groups.ConclusionElevated sputum eosinophils, IL5 and IL8, which have a potential to stimulate airway remodelling, might be a useful non-invasive biomarkers and therapeutic targets of accelerated FEV1 decline in asthma patients.
       
  • Proteomics profiling of epithelium-derived exosomes from nasal polyps
           revealed signaling functions affecting cellular proliferation
    • Abstract: Publication date: Available online 8 January 2020Source: Respiratory MedicineAuthor(s): Min Zhou, Kai Sen Tan, Wei-jie Guan, Li-jie Jiang, Jie Deng, Wen-xiang Gao, Yew Mun Lee, Zhao-feng Xu, Xin Luo, Chen Liu, Jian-bo Shi, Yinyan LaiBackgroundNasal polyps are a significantly associated pathology of chronic rhinosinusitis (CRS) whose mechanisms of pathogenesis are not fully elucidated, especially the interaction of the polyp with its environment that allows its growth on the nasal epithelial lining. Exosomes are nanovesicles that serve important biological functions, including cell-to-cell signaling and communication.ObjectiveHence, we sought to explore the roles of the epithelial-derived exosomal proteome obtained from the human nasal epithelium in the modulation of CRS with nasal polyp (CRSwNP) pathogenesis.MethodsWe sampled exosomes from nasal lavage fluid and primary human nasal epithelial cells (hNECs) from healthy controls and patients with CRSwNP with and without coexisting asthma. The presence of exosomes was confirmed using a NanoSight assay, transmission electron microscopy and western blotting. The exosomal proteome was profiled with mass spectrometry. The Cell Counting Kit-8 was used to confirm the roles of exosomes in mediating cellular proliferation.ResultsThe hNEC-derived exosomes from diseased epithelium contained differentially expressed proteins that were mainly involved in epithelial remodeling via pathways such as p53. An in vitro study further demonstrated that epithelial-derived exosomes from patients with CRSwNP (with and without coexisting asthma) significantly reduced the rate of proliferation of control hNECs at an effective concentration of ≥10 μg/ml.ConclusionsExosomes secreted by hNECs from patients with CRSwNP, regardless of their coexistence with asthma, are laden with proteins that influence cell proliferation pathways, potentially leading to remodeling of the sinonasal mucosa.Graphical abstractDiseased (CRSwNP with and without coexisting asthma) human nasal epithelial cells (hNECs) were found to communicate with the environment via exosomes. Both healthy and exosomal protein signatures include immune response cytokines. Diseased epithelium-derived exosomes secreted increased cell cycle signatures involved in such as p53 pathway that might contribute to the inhibition of healthy epithelial proliferation, potentially as a mechanism of remodeling.Image 1
       
  • A randomized controlled trial of respiratory physiotherapy in lower
           respiratory tract infections
    • Abstract: Publication date: February 2020Source: Respiratory Medicine, Volume 162Author(s): Alda Marques, Cátia Pinho, Silvia De Francesco, Paula Martins, Joana Neves, Ana OliveiraAbstractIntroductionPhysiotherapy may play a role in the recovery of signs, symptoms and function of patients with lower respiratory tract infections (LRTI) but its effectiveness is still controversial.ObjectivesTo assess the effects of respiratory physiotherapy compared with standard pharmacological care on symptoms and function in outpatients with LRTI.DesignSingle-blind, randomised controlled trial.SettingOutpatients were recruited from the casualties of a central hospital.ParticipantsOutpatients with LRTI were recruited and randomly allocated to the control (pharmacological) or experimental (pharmacological and respiratory physiotherapy) group.InterventionThe intervention consisted of conventional pharmacological treatment and conventional pharmacological treatment plus respiratory physiotherapy. Respiratory physiotherapy included breathing and airway clearance techniques, exercise training and education during 3-weeks, 3 times per week.Main outcome measurePrimary outcome measures - occupation rate of wheezes Wh%; Secondary outcome measures - number of crackles, peripheral oxygen saturation (SpO2) modified Borg scale (mBorg), modified Medical Research Council scale (mMRC), 6-min walk test (6MWT), forced expiratory volume in 1 s and forced vital capacity, and volume and density of the lung and bronchial tree volume.ResultsNinety-seven patients (53 controls and 44 experimental) completed the intervention. After the intervention, both groups improved significantly in all variables (0.0001 
       
  • Age- and sex-dependent differences in patients with severe asthma included
           in the German Asthma Net cohort
    • Abstract: Publication date: Available online 3 January 2020Source: Respiratory MedicineAuthor(s): Katrin Milger, Stephanie Korn, Roland Buhl, Eckard Hamelmann, Felix JF. Herth, Monika Gappa, Nora Drick, Jan Fuge, Hendrik SuhlingAbstractBackgroundSevere asthma affects less than 5% of asthmatics, but is associated with high costs and increased mortality. The aim of this study was to assess age- and sex-dependent differences in this patient group.MethodsRetrospective analysis of 1317 children and adults with severe asthma who are included in the German Asthma Net registry.ResultsThere were more adults than children in the registry and patients’ mean age was 52. Apart from children
       
  • Protective effect of FBXL10 in myocardial ischemia reperfusion injury via
           inhibiting endoplasmic reticulum stress
    • Abstract: Publication date: January 2020Source: Respiratory Medicine, Volume 161Author(s): Jie Gao, Yulin Guo, Yan Liu, Jun Yan, Jian Zhou, Xiangguang An, Pixiong SuAbstractObjectiveThe aim of the study was to investigate the mechanism and effect of FBXL10 in myocardial ischemia reperfusion injury in vivo and in vitro.MethodsThe myocardial ischemia reperfusion (I/R) model was established by 30 min of coronary occlusion followed by 2 h of reperfusion in rats. Western blot and TUNEL assay were used to measure the apoptosis during I/R. The expression levels of endoplasmic reticulum related proteins in myocardial tissues and H9c2 cells were detected by immunohistochemistry staining and immunofluorescence staining. Flow cytometry and CCK-8 were used to detect the apoptosis and viability of H9c2 cells.ResultsThe results revealed that FBXL10 significantly reduced myocardial infarction, improved the pathological morphology of myocardium, markedly reduced inflammatory response in the myocardial ischemia reperfusion rats. Moreover the expressions of endoplasmic reticulum stress key proteins were caused by I/R were suppressed significantly by FBXL10 treatment, including CHOP, GRP78, ATF4 and p-PERK. Additionally FBXL10 inhibited the expression of endoplasmic reticulum stress key proteins in H/R H9c2 cells. Furthermore, FBXL10 reduced the levels of apoptotic cells and inflammatory response compared with I/R and H/R group.ConclusionTaken together, we found that FBXL10 could attenuate I/R injury through inhibiting endoplasmic reticulum stress (ERs).
       
  • The role of inspiratory flow in selection and use of inhaled therapy for
           patients with chronic obstructive pulmonary disease
    • Abstract: Publication date: January 2020Source: Respiratory Medicine, Volume 161Author(s): Donald A. MahlerAbstractInhalation therapy is the mainstay of chronic obstructive pulmonary disease management, and inhaler selection can have a profound impact on drug delivery and medication adherence, as well as on treatment outcomes. Although multiple delivery systems, such as pressurized metered-dose inhalers, dry powder inhalers, slow-mist inhalers, and nebulizers, are available, clinical benefits achieved by patients rely on effective delivery of the inhaled medication to the airways. Among several factors influencing drug deposition, inspiratory flow is one of the most important. Inspiratory flow impacts drug delivery and subsequent clinical efficacy, making it necessary to adequately train patients to ensure correct inhaler use. Peak inspiratory flow is the maximal airflow generated during a forced inspiratory maneuver. Health care professionals need to select the appropriate delivery system after carefully considering patient characteristics, including lung function, optimal inspiratory flow, manual dexterity, and cognitive function. Herein, the role of inspiratory flow in the selection and use of inhaled therapy in patients with COPD is reviewed.
       
  • Prognostic value of simple measures of physical function and muscle
           strength in COPD: A systematic review
    • Abstract: Publication date: January 2020Source: Respiratory Medicine, Volume 161Author(s): Daniela Massierer, Waleed Alsowayan, Vanessa Pereira Lima, Jean Bourbeau, Tania Janaudis-FerreiraAbstractPurposeThere has been an increased interest in simple measures of physical function and muscle strength that can be used in all clinical settings to assess individuals with chronic obstructive pulmonary disease (COPD) and predict their prognosis. The main objective was to examine the prognostic value of simple measures of physical function and muscle strength in relation to exacerbation, hospitalization and mortality in individuals with COPD.MethodsMedline, EMBASE, Cochrane and Web of Science were searched. We included prospective observational studies that examined the prognostic value of simple performed-based tests or self-reported measures of physical function or muscle strength in relation to exacerbation, hospitalization and mortality in individuals with COPD.ResultsSeven articles met the inclusion criteria. The most commonly used tests were the handgrip strength (HGS) (n = 4) and 1-min sit-to-stand (STS) (n = 2). There were considerable variations in terms of characteristics of patients included, setting of recruitment, type of tests used, duration of follow-up and outcome measures of interest. The majority of the studies were classified as having “fair” or “poor” methodological quality.ConclusionsThere is a limited number of studies examining the prognostic value of simple measures of physical function and muscle strength in relation to exacerbations, hospitalizations and mortality in individuals with COPD. To date, the HGS and 1-min STS tests are the most studied tests and seem to be suitable for prognosis purposes in individuals with COPD. However, more studies with better methodological quality are needed to confirm these findings.
       
  • Evaluating S100B as a serum biomarker for central neurosarcoidosis
    • Abstract: Publication date: Available online 21 December 2019Source: Respiratory MedicineAuthor(s): B.P. Moss, D.C. Patel, J.O. Tavee, D.A. CulverAbstractBackgroundS100B is a calcium-binding protein found primarily in glial cells. In the setting of neuronal injury and disruption of the blood brain barrier, S100B can leak into the cerebrospinal fluid and systemic circulation.ObjectivesTo determine if serum S100B distinguishes patients with central neurosarcoidosis (NS) from patients with extra-neurologic sarcoidosis (ENS) and healthy controls, and if S100B levels correlate with MRI measures of disease burden.MethodsPatients were enrolled from the Cleveland Clinic Sarcoidosis Center. Patients with traumatic brain injury, central nervous system (CNS) infections, CNS malignancy, neurodegenerative disorders, schizophrenia, bipolar disorder, or melanoma were excluded. S100B levels were compared between patients with NS, ENS, and healthy controls, and between NS patients with varying degrees of post-contrast enhancement on MRI.ResultsMedian (interquartile range) S100B levels were 101 pg/mL (92, 136) for 11 NS patients, 89 pg/mL (73, 107) for 11 ENS patients, and 60 pg/mL (39, 74) for 26 healthy controls. There was a significant difference between NS and control groups (p = 0.01). The difference between NS and ENS groups did not rise to the level of statistical significance (p = 0.178). S100B levels were significantly different between NS patients with varying degrees of enhancement on MRI (p = 0.04).ConclusionsS100B deserves additional study as a biomarker for CNS injury in NS. It may be useful as a longitudinal measure of disease activity.
       
  • Primary cardiac hospitalizations in pulmonary arterial hypertension:
           Trends and outcomes from 2001 to 2014
    • Abstract: Publication date: Available online 28 November 2019Source: Respiratory MedicineAuthor(s): Eileen M. Harder, Aeron M. Small, Wassim H. FaresAbstractBackgroundHospitalizations in pulmonary arterial hypertension (PAH) are common and are often for cardiac conditions. Using the National (Nationwide) Inpatient Sample (NIS), we examined characteristics and mortality of primary cardiac hospitalizations in PAH from 2001 to 2014.MethodsAdult hospitalizations with any diagnosis code for PAH were identified. Primary cardiac disease was defined as a primary discharge diagnosis of congestive heart failure (CHF), pulmonary heart disease, coronary atherosclerosis, acute myocardial infarction, dysrhythmia, conduction disorder, cardiomyopathy or carditis, heart valve disorder, or cardiac arrest. Temporal trends, characteristics, and in-hospital mortality were analyzed.ResultsFrom 2001 to 2014, there were 207,095 hospitalizations in PAH, of which 100,509 (48.5%) carried a primary cardiac diagnosis. Most primary cardiac hospitalizations in PAH were for CHF, and pneumonia was the most common primary non-cardiac diagnosis. Over the study period, primary cardiac hospitalizations in PAH fell from 52.9% to 41.4% (p 
       
  • Impact of mild-to-moderate exacerbations on outcomes of neuromuscular
           electrical stimulation (NMES) in patients with COPD
    • Abstract: Publication date: Available online 28 November 2019Source: Respiratory MedicineAuthor(s): Roy Meys, Maurice J. Sillen, Frits M.E. Franssen, Anouk A.F. Stoffels, Emiel F.M. Wouters, Hieronymus W.H. van Hees, Bram van den Borst, Peter H. Klijn, Martijn A. Spruit, BASES-consortiumAbstractAcute exacerbations of chronic obstructive pulmonary disease (AECOPD) (PR) and may compromise its outcomes. Neuromuscular electrical stimulation (NMES) seems one of the few exercise modalities that can actually be continued during AECOPD, due to its low burden on the impaired respiratory and cardiovascular system. However, the quality of evidence is low. The purpose of this study was to assess the impact of mild-to-moderate AECOPD on adherence/outcomes of a high-frequency (HF) or low-frequency (LF) NMES training program, as part of inpatient PR, in severely dyspneic, weakened individuals with COPD. 62 patients who received NMES as the sole supervised muscle training modality during an 8‐week PR program (HF-NMES: n = 33; LF‐NMES: n = 29) were analyzed retrospectively. 48.4% experienced ≥1 AECOPD during PR and were classified as exacerbators. Exacerbators completed 75 NMES sessions (interquartile range: 73–78) and were able to increase training intensity with 24 mA (15–39), while non-exacerbators completed 76 sessions (73–79) and increased training intensity with 35 mA (22–50), with no between-group differences (p = 0.474 and p = 0.065, respectively). The median change in 6-min walking distance, cycle endurance time, and isokinetic quadriceps strength and endurance did not differ between the exacerbation and non-exacerbation group. To conclude, the occurrence of mild-to-moderate AECOPD during a PR program primarily focused on NMES, does not affect adherence, intensity, and clinical outcomes in patients with severe COPD. Continuing NMES seems a feasible way to potentially counteract exacerbation-related lower-limb muscle dysfunction and improve outcomes of PR, with HF‐NMES being the preferential muscle training modality.
       
  • Sarcoidosis diagnosis and treatment in Sweden: A register-based assessment
           of variations by region and calendar period
    • Abstract: Publication date: Available online 26 November 2019Source: Respiratory MedicineAuthor(s): Marios Rossides, Susanna Kullberg, Anders Eklund, Johan Grunewald, Elizabeth V. ArkemaAbstractBackgroundIn Sweden, sarcoidosis prevalence varies geographically, but it is unclear whether diagnosis and treatment patterns vary by geographical area and calendar period. We sought to investigate differences in sarcoidosis diagnosis and treatment by healthcare region and calendar period using nationwide register data.MethodsWe included 4777 adults who had at least two ICD-coded visits for sarcoidosis in the National Patient Register (2007–2012). We compared patterns of healthcare use (visits and medication dispensations), and data on sarcoidosis diagnosis and treatment spanning two years before to two years after diagnosis stratified by healthcare region and calendar period at diagnosis.ResultsCompared to other regions, individuals diagnosed in Stockholm were younger, more likely female, and had a higher education level. In all regions, there was an increase in healthcare use at least six months before sarcoidosis diagnosis with small variation among regions. Most patients were diagnosed in pulmonary and internal medicine outpatient clinics, but compared to the national average more patients were diagnosed in rheumatology in the West and ophthalmology and cardiology in the South. Corticosteroid dispensations at diagnosis varied widely by region (48% in the South/Southeast vs. 30% in Stockholm/North). Demographic factors could not explain these differences. We found no differences by calendar period.ConclusionOur findings suggest a six-month delay in sarcoidosis diagnosis irrespective of region. The observed regional variation likely reflects differences in diagnosis and treatment patterns. Stakeholders should ensure diagnosis and treatment recommendations are closely followed.
       
  • Asthma similarities across ProAR (Brazil) and U-BIOPRED (Europe) adult
           cohorts of contrasting locations, ethnicity and socioeconomic status
    • Abstract: Publication date: Available online 26 November 2019Source: Respiratory MedicineAuthor(s): Alvaro A. Cruz, John H. Riley, Aruna T. Bansal, Eduardo V. Ponte, Adelmir Souza-Machado, Paula C.A. Almeida, Valmar Biao-Lima, Maggie Davis, Stewart Bates, Ian M. Adcock, Peter J. Sterk, Kian Fan Chung, N. Alcantara-Neves, P.C.A. Almeida, L. Amorim, M.I. Araujo, K.C. Barnes, M.L. Barreto, E. Belitardo, V. Bião-LimaAbstractBackgroundAsthma prevalence is 339 million globally. ‘Severe asthma’ (SA) comprises subjects with uncontrolled asthma despite proper management.ObjectivesTo compare asthma from diverse ethnicities and environments.MethodsA cross-sectional analysis of two adult cohorts, a Brazilian (ProAR) and a European (U-BIOPRED). U-BIOPRED comprised of 311 non-smoking with Severe Asthma (SAn), 110 smokers or ex-smokers with SA (SAs) and 88 mild to moderate asthmatics (MMA) while ProAR included 544 SA and 452 MMA. Although these projects were independent, there were similarities in objectives and methodology, with ProAR adopting operating procedures of U-BIOPRED.ResultsAmong SA subjects, age, weight, proportion of former smokers and FEV1 pre-bronchodilator were similar. The proportion of SA with a positive skin prick tests (SPT) to aeroallergens, the scores of sino-nasal symptoms and quality of life were comparable. In addition, blood eosinophil counts (EOS) and the % of subjects with EOS > 300 cells/μl were not different. The Europeans with SA however, were more severe with a greater proportion of continuous oral corticosteroids (OCS), worse symptoms and more frequent exacerbations. FEV1/FVC pre- and post-bronchodilator were lower among the Europeans. The MMA cohorts were less comparable in control and treatment, but similar in the proportion of allergic rhinitis, gastroesophageal reflux disease and EOS>3%.ConclusionsProAR and U-BIOPRED cohorts, with varying severity, ethnicity and environment have similarities, which provide the basis for global external validation of asthma phenotypes. This should stimulate collaboration between asthma consortia with the aim of understanding SA, which will lead to better management.
       
  • Prevalence and prognosis of respiratory muscle weakness in heart failure
           patients with preserved ejection fraction
    • Abstract: Publication date: Available online 20 November 2019Source: Respiratory MedicineAuthor(s): Nobuaki Hamazaki, Kentaro Kamiya, Ryota Matsuzawa, Kohei Nozaki, Takafumi Ichikawa, Shinya Tanaka, Takeshi Nakamura, Masashi Yamashita, Emi Maekawa, Chiharu Noda, Minako Yamaoka-Tojo, Atsuhiko Matsunaga, Takashi Masuda, Junya AkoBackgroundAlthough respiratory muscle weakness (RMW) is known to predict prognosis in patients with heart failure with reduced ejection fraction (HFrEF), RMW prevalence and its prognosis in those with preserved ejection fraction (HFpEF) remain unknown. We aimed to investigate whether the RMW predicted mortality in HFpEF patients.MethodsWe conducted a single-centre observational study with consecutive 1023 heart failure patients (445 in HFrEF and 578 in HFpEF). Maximal inspiratory pressure (PImax) was measured to assess respiratory muscle strength at hospital discharge, and RMW was defined as PImax
       
  • CXCL9 and CXCL10 are differentially associated with systemic organ
           involvement and pulmonary disease severity in sarcoidosis
    • Abstract: Publication date: Available online 20 November 2019Source: Respiratory MedicineAuthor(s): Nicholas K. Arger, Melissa E. Ho, Isabel E. Allen, Bryan S. Benn, Prescott G. Woodruff, Laura L. KothAbstractBackgroundSarcoidosis is a granulomatous inflammatory disease with limited blood markers to predict outcomes. The interferon-gamma (IFN-γ)-inducible chemotactic cytokines (chemokines), CXCL9 and CXCL10, are both increased in sarcoidosis patients, yet they possess important molecular differences. Our study determined if serum chemokines correlated with different aspects of disease severity.MethodsWe measured CXCL9 and CXCL10 serum levels at initial study visits and longitudinally in sarcoidosis subjects using ELISA. We examined these chemokines’ relationships with pulmonary, and organ involvement outcomes, their gene expression, peripheral blood immune cell populations, and immunosuppression use.ResultsHigher CXCL10 levels negatively correlated with FVC, TLC, and DLCO at subjects’ initial visit and when measured repeatedly over two years. CXCL10 also positively correlated with longitudinal respiratory symptom severity. Additionally, for every log10(CXCL10) increase, the risk of longitudinal pulmonary function decline increased 8.8 times over the 5-year study period (95% CI 1.6–50, p = 0.014, log10(CXCL0) range 0.84–2.7). In contrast, CXCL9 levels positively correlated with systemic organ involvement at initial study visit (1.5 additional organs involved for every log10(CXCL9) increase, 95% CI 1.1–2.0, p = 0.022, log10(CXCL9) range 1.3–3.3). CXCL10, not CXCL9, positively correlated with its own blood gene expression and monocyte level. Immunosuppressive treatment was associated with lower levels of both chemokines.ConclusionsIn sarcoidosis subjects, serum CXCL9 levels correlated with systemic organ involvement and CXCL10 levels strongly correlated with respiratory outcomes, which may ultimately prove helpful in clinical management. These differing associations may be due to differences in cellular regulation and tissue origin.
       
  • The senescence-associated matricellular protein CCN1 in plasma of human
           subjects with idiopathic pulmonary fibrosis
    • Abstract: Publication date: Available online 19 November 2019Source: Respiratory MedicineAuthor(s): Tejaswini Kulkarni, Ashish R. Kurundkar, Young-il Kim, Joao de Andrade, Tracy Luckhardt, Victor J. ThannickalAbstractIntroductionCellular senescence has been linked to the pathogenesis of idiopathic pulmonary fibrosis (IPF). CCN1 is a matricellular protein that has been shown to induce cellular senescence and contribute to lung fibrosis in pre-clinical models. In this report, we determined plasma CCN1 levels in patients with IPF and its potential role in clinical outcomes.Methods and ResultsWe evaluated 88 patients diagnosed with IPF at the University of Alabama at Birmingham. CCN1 levels were measured in plasma specimens by ELISA. The primary outcome measure was transplant-free survival (TFS) duration. High-CCN1 levels were associated with a lower transplant-free survival independent of %FVC and %DLCO compared to patients with low plasma CCN1 (HR = 2.15; 95%CI 1.04–4.45, p = 0.04).ConclusionThis study demonstrates that plasma levels of CCN1 may be predictive of survival in IPF. Given the plausible role of CCN1 in cellular senescence and pathobiology of IPF, the predictive value of CCN1 in disease progression among patients with IPF warrants further investigation.
       
  • Acute respiratory failure in interstitial lung disease complicated by
           pulmonary hypertension
    • Abstract: Publication date: Available online 19 November 2019Source: Respiratory MedicineAuthor(s): Cyrus A. Vahdatpour, Melinda L. Darnell, Harold I. PalevskyAbstractInterstitial lung disease represents a group of diffuse parenchymal lung diseases with overwhelming morbidity and mortality when complicated by acute respiratory failure. Recently, trials investigating outcomes and their determinants have provided insight into these high mortality rates. Pulmonary hypertension is a known complication of interstitial lung disease and there is high prevalence in idiopathic pulmonary fibrosis, connective tissue disease, and sarcoidosis subtypes. Interstitial lung disease associated pulmonary hypertension has further increased mortality with acute respiratory failure, and there is limited evidence to guide management. This review describes investigations and management of interstitial lung disease associated acute respiratory failure complicated by pulmonary hypertension. Despite the emerging attention on interstitial lung disease associated acute respiratory failure and the influence of pulmonary hypertension, critical care management remains a clinical and ethical challenge.
       
  • Factors predicting length of stay in bronchiolitis
    • Abstract: Publication date: Available online 16 November 2019Source: Respiratory MedicineAuthor(s): Kamal Masarweh, Michal Gur, Ronit Leiba, Ronen Bar-Yoseph, Yazeed Toukan, Vered Nir, Guy Gut, Yael Ben-David, Fahed Hakim, Lea BenturAbstractIntroductionDespite advances in medical knowledge, the treatment of viral bronchiolitis is mainly supportive. Antiviral therapies are being investigated in clinical trials. Identifying population-attributable risk factors for RSV hospitalization may help prioritizing targeted treatment.AimTo utilize MDClone, a data acquisition tool, to examine factors associated with the risk of hospitalization and length of stay (LOS) in bronchiolitis.MethodsA single tertiary medical center retrospective study. Infants discharged with a diagnosis of bronchiolitis between January 2001 and March 2019 were included. Demographic, clinical, laboratory, microbiologic parameters and co-morbidities were collected. Correlations with the risk of hospitalization and LOS were examined.ResultsA total of 4793 infants with bronchiolitis, 3851 (80.3%) previously healthy, were seen; 975 visited emergency room only; 3311 were hospitalized in pediatric wards and 507 required pediatric intensive care unit. O2 saturation, age and fever correlated with the risk of hospitalization (OR = 0.703, p 
       
  • Factors influencing decline in quality of life in smokers without airflow
           obstruction: The COPDGene study
    • Abstract: Publication date: Available online 15 November 2019Source: Respiratory MedicineAuthor(s): Trisha M. Parekh, Smita Bhatia, Andrea Cherrington, Young-il Kim, Allison Lambert, Anand Iyer, Elizabeth A. Regan, Dawn L. DeMeo, MeiLan Han, Mark T. DransfieldAbstractIntroductionCurrent and former smokers with normal spirometry and with Preserved Ratio Impaired Spirometry (PRISm) experience respiratory events similar to chronic obstructive pulmonary disease (COPD) exacerbations. Exacerbations significantly reduce quality of life (QoL) in COPD patients however the effect of respiratory exacerbations on QoL in these groups is unknown. We hypothesized that exacerbations and change in exacerbation status would predict QoL decline among normal spirometry and PRISm participants in COPDGene.MethodsCOPDGene is a multicenter, longitudinal study in the U.S. designed to identify genetic determinants of COPD. We enrolled study subjects in Phase 1 of COPDGene and performed multivariable logistic regression models to determine independent predictors of decline in quality of life [>4 points on the St George's Respiratory Questionnaire (SGRQ)]. Separate analyses were performed for current and former smokers with normal spirometry and PRISm. Frequent exacerbator status was defined by > 2 moderate or>1 severe exacerbations in the year prior to the baseline and year 5 follow-up visits.ResultsIndependent predictors of QoL deterioration included current smoking, higher exacerbation frequency, and a change from infrequent to frequent exacerbation status (REF: infrequent to infrequent exacerbation status) in both groups [PRISm (OR = 3.15,95%CI, 1.67–5.94), normal spirometry (OR = 4.72,95%CI, 3.25–6.86)]. A change from frequent to infrequent exacerbation status did not lower the odds of QoL decline in either cohort.ConclusionContinued smoking and the onset of frequent exacerbations were predictors of QoL decline in smokers with normal spirometry and PRISm. Further studies are needed to identify modifiable factors associated with decline in QoL in smokers.
       
  • Efficacy and safety of inhaled once-daily low-dose indacaterol
           acetate/mometasone furoate in patients with inadequately controlled
           asthma: Phase III randomised QUARTZ study findings
    • Abstract: Publication date: Available online 14 November 2019Source: Respiratory MedicineAuthor(s): Oliver Kornmann, Janos Mucsi, Nadezda Kolosa, Lorraine Bandelli, Biswajit Sen, Lisa C. Satlin, Peter D'AndreaAbstractBackgroundGlobal initiative for asthma (GINA) 2019 recommends adding a long-acting β2-agonist (LABA) to an inhaled corticosteroid (ICS) as a maintenance controller therapy in patients with inadequately controlled asthma. Indacaterol acetate (IND, a LABA) in combination with mometasone furoate (MF, an ICS) is under development for the treatment of these patients.ObjectiveThis phase III QUARTZ was a multicentre, randomised, double-blind, double-dummy and parallel-group study to assess the efficacy and safety of low-dose IND/MF 150/80 μg once daily (o.d.) versus MF 200 μg o.d. in adult and adolescent patients with inadequately controlled asthma.MethodsEligible patients (n = 802) were randomised (1:1) to receive either low-dose IND/MF 150/80 μg o.d. via Breezhaler® or MF 200 μg o.d. via Twisthaler® for 12 weeks. Primary endpoint was trough forced expiratory volume in one second (FEV1) and key secondary endpoint was Asthma Control Questionnaire (ACQ-7) treatment difference after 12-week treatment. Other secondary endpoints included ACQ-7 responder analysis, morning and evening peak expiratory flow, Asthma Quality of Life Questionnaire total score, rescue medication use, daily symptom score, nighttime awakenings and rate of exacerbations, evaluated over 12-week treatment. Safety was also assessed including serious asthma outcomes.ResultsLow-dose IND/MF significantly improved trough FEV1 (least squares mean treatment difference [LSMTD]: 0.182 L; p 
       
  • Long-term ambient air pollution exposure and respiratory impedance in
           children: A cross-sectional study
    • Abstract: Publication date: Available online 1 October 2019Source: Respiratory MedicineAuthor(s): Sajal DeAbstractObjectivesThe present study was aimed to compare the respiratory impedance of children residing in areas with different ambient air pollution (AAP).MethodsA comparative cross-sectional pilot study was carried out in healthy school children of two cities in India i.e. Agra and Bhopal. Agra is one of the most polluted cities of India and AAP of Agra is much higher as compared to Bhopal, the reference city in the present study. The respiratory impedance was measured at 5, 11, and 19 Hz by forced oscillation technique (FOT). The anthropometric parameters, respiratory resistance at 5 Hz (R5), small airway resistance (R5-19), and reparatory reactance at 5 Hz (X5) of children from above two cities were compared by Student's t-test.ResultsA total 114 children (57 boys) from Agra and 151 children (76 boys) from Bhopal aged 9–16 years were recruited. The children from Agra were younger (11.9 ± 1.9 yr vs. 13.1 ± 2.2 yr, p 
       
  • Asthma-associated bronchiectasis: More attention needed!
    • Abstract: Publication date: Available online 12 September 2019Source: Respiratory MedicineAuthor(s): Bi-cui Liu, Ting-xuan Huang, Dan Yang, Ling Yang, Chun-Tao Liu
       
  • Device-handling study of a novel breath-actuated inhaler,
           Synchrobreathe®, versus a pMDI
    • Abstract: Publication date: Available online 28 May 2019Source: Respiratory MedicineAuthor(s): Santhalingam Balamurugan, Komal Kirti Apte, Bhanu Pratap Singh, Ashish Kumar Deb, Chandrahas Deshmukh, Kinjal Modi, Ajay Godse, Raja Dhar, Keya Rani Lahiri, Virendra Singh, Hiren Pandya, Sujeet Rajan, Abhijit Vaidya, Vaibhav Gaur, Jaideep GogtayAbstractIntroductionSynchrobreathe®, a new-generation, novel breath-actuated inhaler (BAI) can address the key issues arising during the use of both pressurised metered dose inhalers ([pMDIs]; hand-breath coordination) and dry powder inhalers ([DPIs]; high inspiratory flow required) with respect to optimal drug deposition.Materials and methodsThis was an open-label, prospective, 2-week, multicentre study that assessed device handling, ease of use, errors and participant perception regarding the use of Synchrobreathe® versus a pMDI in patients with chronic obstructive pulmonary disease (COPD) (n = 162) or asthma (n = 239) and inhaler-naïve healthy volunteers (n = 59). Ability to use the device without errors at the first attempt, total number of errors before and after training, time taken to use the device correctly and total number of training sessions, and number of attempts to perform the correct technique on Day 1 and Day 14 were evaluated. Device handling and preference questionnaires were also administered on Day 14.ResultsOf 460 participants, 421 completed the study. The number of participants using Synchrobreathe without any error after reading the patient information leaflet (PIL) was significantly low (p 
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 34.204.200.74
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-